Phase 1 Trial of VAS-101 Gel for Improved Curcumin Absorption in Sickle Cell Disease
A clinical trial is underway to evaluate the efficacy of VAS-101, a skin gel containing curcumin, in patients with stable sickle cell disease.
Phase I
sickle cell disease patients
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The ongoing clinical trial of VAS-101 represents a potential breakthrough in the treatment of sickle cell disease, a condition with significant unmet medical needs. Success in this trial could shift the treatment landscape, prompting competitors to innovate in similar therapeutic areas.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor enrollment progress, interim results on safety and efficacy, and any announcements regarding further development plans.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.